Key result
Lower selenoprotein P and renalase levels are linked to worse pulse pressure and LVMI.
Why the study?
This study aimed to assess the relationship between the antioxidants selenoprotein P, peroxiredoxin-5, and renalase and selected cardiovascular consequences evaluated by ABPM and echocardiography.
Do levels of selenoprotein P, peroxiredoxin-5, and renalase correlate with cardiovascular parameters on ABPM and ECHO in patients evaluated for OSA?
Cross-Sectional (n=112)
No
Do levels of selenoprotein P, peroxiredoxin-5, and renalase correlate with cardiovascular parameters on ABPM and ECHO in patients evaluated for OSA?
Effect estimate: r = -0.32
p-value: p=<0.05
Lower levels of selenoprotein P and renalase are associated with unfavorable cardiovascular parameters, suggesting their potential utility in cardiovascular risk stratification.
Does not support clinical adoption in OSA; leaves open prospective validation of selenoprotein P and renalase as cardiovascular biomarkers.
This study aimed to assess the relationship between chosen antioxidants, namely selenoprotein P (SELENOP), peroxiredoxin-5 (Prdx-5), renalase and selected cardiovascular consequences tested in ambulatory blood pressure monitoring (ABPM) and echocardiography (ECHO). In our work, cardiovascular consequences refer to higher mean blood pressure (MBP) and pulse pressure (PP) on ABPM, as well as to left atrial enlargement (LAE), left ventricular hypertrophy (LVH) and lower left ventricular ejection fraction (LVEF%) on ECHO. The study group consisted of 101 consecutive patients admitted to the Department of Internal Medicine, Occupational Diseases and Hypertension to verify the diagnosis of Obstructive Sleep Apnoea (OSA). Each patient underwent full polysomnography, blood tests, ABPM and ECHO. Both selenoprotein-P and renalase levels correlated with different ABPM and ECHO parameters. We found no correlation between the peroxiredoxin-5 level and none of the tested parameters. We point to the possible application of SELENOP plasma-level testing in the initial selection of high cardiovascular-risk patients, especially if access to more advanced examinations is limited. We further suggest SELENOP measurement as a possible indicator of patients at increased left ventricular hypertrophy risk who should be of particular interest and may benefit from ECHO testing.
No takes yet. Share an insight, caveat, or question.
Czerwińska et al. (2023) conducted a cross-sectional in Obstructive Sleep Apnoea (OSA) evaluation (n=112). Selenoprotein P, peroxiredoxin-5, and renalase levels was evaluated on Correlation between selenoprotein P and pulse pressure (PP) (r = -0.32, p=<0.05). Lower selenoprotein P and renalase levels were significantly associated with unfavorable cardiovascular parameters, including higher pulse pressure and left ventricular mass index.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: